Zepbound and Mounjaro share tirzepatide but carry different labels. Here is what the names change, what they leave alone, and what to check before your next refill.
You're at the pharmacy counter, and the screen says Zepbound. Last week a friend showed you a Mounjaro box from her fridge, and now you're wondering whether one of them is a copy. Neither is a knockoff. Zepbound vs Mounjaro is less about which product is better and more about which name matches your prescription, your diagnosis, and your insurance. Both brands contain tirzepatide, a dual GIP and GLP-1 receptor agonist made by Eli Lilly. This post explains what the name changes and what it leaves alone, so you end up with the right product for the right reason.
Why one molecule carries two names
Tirzepatide is the active ingredient in both products. You can confirm this in the current FDA prescribing information for Mounjaro and for Zepbound, which you'll find through Drugs@FDA or DailyMed. Same molecule, same manufacturer, same core medicine.
So what does the name change? Mostly the label. Each brand is tied to the uses the FDA approved for it, and those approved uses shape who the product is meant for and how a prescription gets justified. The molecule stays put.
What the FDA labels actually say about each name
Mounjaro received FDA approval in May 2022 as an add-on to diet and exercise for adults with type 2 diabetes. Zepbound followed in November 2023 for chronic weight management in adults with obesity, or with overweight plus at least one weight-related condition. In December 2024, Zepbound received an additional approval for moderate to severe obstructive sleep apnea in adults with obesity.
The indication is what separates the labels. Coverage decisions often start with the approved use printed on the label, so a mismatch between your diagnosis and the brand on your prescription can cause trouble later. Labels get updated, too. Check the current prescribing information on Drugs@FDA before you rely on any date or indication, including the ones you read here. Lilly's own news releases, posted on its investor site, record each approval.
What stays the same across both brands
Both products share the same active ingredient, the same mechanism, and a similar weekly subcutaneous injection schedule. You inject once a week under the skin. That routine looks identical whether the box says Zepbound or Mounjaro.
Dosing starts low. The labels generally begin at 2.5 mg once weekly, then increase in steps of 2.5 mg, with maintenance doses listed for each product. The label sets those steps, but your prescriber decides the pace based on how you tolerate the medicine and what you need.
Both labels carry a boxed warning about thyroid C-cell tumors seen in rodent studies. The labels also contraindicate use in people with a personal or family history of medullary thyroid carcinoma, or with multiple endocrine neoplasia syndrome type 2 (MEN 2). If either history applies to you, say so before you start.
The labels list nausea, diarrhea, vomiting, and constipation among common side effects. They also warn about pancreatitis and gallbladder problems. A different name on the box doesn't change that safety conversation, so keep it on your list for every appointment.
How the name shows up at the pharmacy and with insurance
A prescription usually names one brand. The pharmacy fills exactly what the prescriber wrote and what your plan covers. If the prescription says Zepbound, the pharmacist looks for Zepbound, even though the active ingredient matches Mounjaro.
As far as the FDA's records go, no generic tirzepatide is approved in the US. That means a pharmacy can't swap one brand for the other the way it often does with generic small-molecule drugs. Generic approvals are listed in Drugs@FDA, so check there for the status on the day you fill.
Insurance adds another layer. Some formularies list only one name, cover one indication, or require prior authorization tied to a specific diagnosis. Rules differ from plan to plan, so read your plan's drug list and ask the insurer which documents it needs before the pharmacy calls.
When you pick up the box, ask the pharmacist to read the product name, strength, and NDC against the prescription. The NDC, or National Drug Code, is the number printed on the carton that identifies the product and package. The FDA's NDC Directory lets you look it up. If the name or strength doesn't match, pause before you leave.
Tracking matters here too. Write down the brand name on each refill, not just the date. Keeping a dose log on TirzeBlog makes it easier to spot when the name changes between fills, which helps if a claim gets questioned later.
What changes in Brazil
In Brazil, availability depends on ANVISA registration, and that status varies by brand and presentation. Don't assume both names are sold in the same way. Look up the product in the ANVISA medicine consultation portal, reachable from the agency's official site at gov.br/anvisa, and check which presentations are listed at the time you search. Whatever a seller or an older article says, the registry is the source to trust.
Compare the product name, concentration, and presentation on the package with your prescription. If anything doesn't line up, ask the pharmacist before you accept the product. A listing that shows one brand name doesn't prove the product in the box matches it, so verify the details in hand.
Keep a record of the product name, lot number, and registration number for every box you receive. Having those three details together helps if a pharmacy, a doctor, or a regulator asks questions later. Some readers use TirzeBlog as a log companion next to their injection dates, which keeps the details in one place.
A checklist for your next conversation with your prescriber
Bring these three questions to your next appointment:
- Which indication does this prescription rely on, and does it match my diagnosis and my insurance?
- Do the strength and the pen or vial format match what I will actually receive?
- What should I do if the pharmacy hands me a product with a different name than the one prescribed?
A clear record of names, doses, and lot numbers helps with any future insurance or pharmacy question, and it gives your prescriber something concrete to review. You can keep your records on tirzeblog.com if that suits your routine, though a notebook or spreadsheet works just as well.
FAQ
Is Zepbound the same as Mounjaro?
Both contain tirzepatide, made by Eli Lilly. The labels differ because each brand is approved for different uses. Check the indication on your prescription before you assume they're interchangeable.
Can a pharmacy swap Zepbound for Mounjaro?
Generally not on its own. The prescription names a brand, and as far as the FDA's records show, no generic tirzepatide is approved in the US. Ask your prescriber before you accept any change.
Why does my insurance cover one name but not the other?
Coverage depends on your plan's formulary and on the approved indication tied to your diagnosis. Read your plan's drug list and ask whether prior authorization applies.
Which name fits a type 2 diabetes diagnosis?
Mounjaro is the brand the FDA approved for adults with type 2 diabetes. Your prescriber can confirm which product fits your situation and your coverage.
Sources
Disclaimer: This content is for informational purposes only and does not replace professional medical advice. Always consult your doctor before starting, changing or stopping any treatment.
Ozempro — Monitor GLP-1
Never miss a dose and track everything
Injection reminders, a dose history and a side-effects diary — all organized to bring to your appointment.
or download the app
